Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Return on Equity (2016 - 2025)

Protalix BioTherapeutics has reported Return on Equity over the past 15 years, most recently at 0.04% for Q4 2025.

  • Quarterly results put Return on Equity at 0.04% for Q4 2025, down 25.0% from a year ago — trailing twelve months through Dec 2025 was 0.04% (down 25.0% YoY), and the annual figure for FY2025 was 0.04%, down 25.0%.
  • Return on Equity for Q4 2025 was 0.04% at Protalix BioTherapeutics, down from 0.2% in the prior quarter.
  • Over the last five years, Return on Equity for PLX hit a ceiling of 9.66% in Q4 2021 and a floor of 10.46% in Q3 2021.
  • Median Return on Equity over the past 5 years was 0.22% (2024), compared with a mean of 0.53%.
  • Biggest five-year swings in Return on Equity: plummeted -1067bps in 2021 and later soared 1213bps in 2022.
  • Protalix BioTherapeutics' Return on Equity stood at 9.66% in 2021, then plummeted by -87bps to 1.3% in 2022, then tumbled by -109bps to 0.12% in 2023, then surged by 273bps to 0.2% in 2024, then plummeted by -121bps to 0.04% in 2025.
  • The last three reported values for Return on Equity were 0.04% (Q4 2025), 0.2% (Q3 2025), and 0.23% (Q2 2025) per Business Quant data.